Biotech Values

[mcbio]

ARQL

1. 10-Q states:"The MET high tivantinib group (in Marquee trial) showed a substantial improvement in OS relative to control".
However, ARQL management does not intend to do anything prior to ARQL sees the results from ALL four NSCLC trials. This is beyond any common sense. Pucci is either incompetent or an idiot. The CEO must be fired ASAP. Something has to be done about it.

LOL Pucci is not committing to another P3 in NSCLC because tivantinib is now well behind METMAB and if METMAB results pan out, there will be a different standard of care by the time any tivantinib P3 NSCLC results would read out. I don't view that as an unreasonable thought process. He did say in the CC that if METMAB should fail, then there could be a path forward in NSCLC for tivantinib (though on the other hand wouldn't this call into question the value of MET as target in NSCLC?).

2. I heard that ARQL will have an oral presentation for its Ph2 mCRC. Therefore, the results must be interesting. But again, ARQL is in no hurry to review this data and move forward prior to ASCO. Why?

Pucci said in the CC that the data is "gonna be quite interesting." Who knows what that ultimately will translate to in terms of actual results we see but I would note that Pucci is generally a pretty cautious speaker I find. I don't think there's a path forward in CRC but the hope is there will be more validation for tivantinib in high MET.

3. I also heard that ARQL wants to take ARQ-092 thru Ph2 by themselves even as there was/is an outside interest for ARQ-092 development.

That's because the CEO wants to increase the value of the drug further. I have no problem with that as ARQL has the cash to advance further and create more value for the drug.